WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...
– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced startup for a Phase 2 clinical trial in COPD; on track for first patient to be dosed in H2...
WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus...
WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.6 | 19.2616372392 | 18.69 | 23.79 | 18 | 163966 | 20.6507672 | CS |
4 | -3.71 | -14.2692307692 | 26 | 29.3 | 17.0885 | 234845 | 22.84548619 | CS |
12 | 0.79 | 3.67441860465 | 21.5 | 29.3 | 17.0885 | 317740 | 23.54461109 | CS |
26 | 0.79 | 3.67441860465 | 21.5 | 29.3 | 17.0885 | 317740 | 23.54461109 | CS |
52 | 0.79 | 3.67441860465 | 21.5 | 29.3 | 17.0885 | 317740 | 23.54461109 | CS |
156 | 0.79 | 3.67441860465 | 21.5 | 29.3 | 17.0885 | 317740 | 23.54461109 | CS |
260 | 0.79 | 3.67441860465 | 21.5 | 29.3 | 17.0885 | 317740 | 23.54461109 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관